Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
BM Scirica, DL Bhatt, E Braunwald… - … England Journal of …, 2013 - Mass Medical Soc
Background The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
ME Cobble, R Frederich - Cardiovascular Diabetology, 2012 - Springer
Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular (CV)
disease; however, conclusive evidence that glycemic control leads to improved …
disease; however, conclusive evidence that glycemic control leads to improved …
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
R Frederich, JH Alexander, FT Fiedorek… - Postgraduate …, 2010 - Taylor & Francis
Objective: The objective was to assess the relative risk (RR) for cardiovascular (CV) events
across all 8 randomized phase 2/3 trials evaluating saxagliptin in patients with type 2 …
across all 8 randomized phase 2/3 trials evaluating saxagliptin in patients with type 2 …
The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction …
OBJECTIVES: Saxagliptin, a dipeptidyl peptidase 4 inhibitor, improves glycemic control in
patients with type 2 diabetes mellitus (T2DM) by increasing endogenous active, intact …
patients with type 2 diabetes mellitus (T2DM) by increasing endogenous active, intact …
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial
OBJECTIVE The glycemic management of patients with type 2 diabetes mellitus (T2DM) and
renal impairment is challenging, with few treatment options. We investigated the effect of …
renal impairment is challenging, with few treatment options. We investigated the effect of …
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial
R Frederich, R McNeill, N Berglind, D Fleming… - Diabetology & Metabolic …, 2012 - Springer
Background The aim of this study was to assess efficacy and safety of saxagliptin
monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and …
monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and …
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial
OBJECTIVE To examine the safety and cardiovascular (CV) effects of saxagliptin in the
predefined elderly (≥ 65 years) and very elderly (≥ 75 years) subpopulations of the …
predefined elderly (≥ 65 years) and very elderly (≥ 75 years) subpopulations of the …
Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
J Rosenstock, C Aguilar-Salinas, E Klein… - … medical research and …, 2009 - Taylor & Francis
Objective: To evaluate the efficacy and safety of once-daily saxagliptin monotherapy in
treatment-naïve patients with type 2 diabetes (T2D) and inadequate glycemic control …
treatment-naïve patients with type 2 diabetes (T2D) and inadequate glycemic control …
Saxagliptin
S Dhillon, J Weber - Drugs, 2009 - Springer
Abstract▲ Saxagliptin and its active metabolite M2 are dipeptidyl peptidase-4 inhibitors that
improve glycaemic control by preventing the inactivation of the incretin hormones glucagon …
improve glycaemic control by preventing the inactivation of the incretin hormones glucagon …
Efficacy and safety of saxagliptin in drug‐naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial
CY Pan, W Yang, C Tou… - … research and reviews, 2012 - Wiley Online Library
Background Few studies have assessed the use of new oral anti‐diabetic agents in Asian
populations. This study assesses the efficacy and safety of saxagliptin versus placebo in …
populations. This study assesses the efficacy and safety of saxagliptin versus placebo in …